Solventum Corporation

SOLV Healthcare Medical Instruments & Supplies

Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.

85.81 2.05 −2.33%
Market cap
$15.0B
P/E
10.4×
Fwd P/E
39.0×
Dividend yield
—
F-score
5/9
Altman Z
2.22
Beneish M
−2.07
Dividend safety
n/a

Solventum Corporation (SOLV) Free cash flow

Alert me on Free cash flow

Solventum Corporation's free cash flow for fiscal 2025 was −$10.0M, compared with $805.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$118.0M. Solventum Corporation ranks 53rd of 54 Medical Instruments & Supplies companies by free cash flow.

Free cash flow, annual

Embed this chart

Annual newest first

Period Free cash flow Change
FY2025 −$10.0M —
FY2024 $805.0M (50.46%)
FY2023 $1.6B 13.80%
FY2022 $1.4B —

Quarterly newest first

Period Free cash flow Change
Jun 2026 $144.0M —
Mar 2026 −$273.0M —
Dec 2025 $32.0M —
Sep 2025 −$21.0M —
11 more quarters

Free cash flow against peers

What Free cash flow is

Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.

Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)

The full definition of Free cash flow →

More on SOLV